Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models
暂无分享,去创建一个
M. Beer | B. Corleis | D. Maione | A. Dorhoi | B. Petsch | Jacob Schön | D. Hoffmann | K. Kováčiková | S. Rauch | Lorenz Ulrich | N. Halwe | Charlie Fricke | N. Roth | Stefan O. Mueller | J. Gergen | Kristina Kovacikova
[1] A. Gordon,et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants , 2022, Cell.
[2] S. Ciesek,et al. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice , 2022, Science immunology.
[3] Benjamin Bowe,et al. Acute and postacute sequelae associated with SARS-CoV-2 reinfection , 2022, Nature Medicine.
[4] Larissa B. Thackray,et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice , 2022, Nature Medicine.
[5] Robert J. Fischer,et al. ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants , 2022, Nature Communications.
[6] R. Bull,et al. Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission , 2022, Reviews in medical virology.
[7] B. Petsch,et al. Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses , 2022, bioRxiv.
[8] M. Hassanain,et al. SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study , 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[9] K. Schenke-Layland,et al. Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Minal K. Patel,et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant , 2022, The Lancet Infectious Diseases.
[11] P. McKay,et al. Omicron breakthrough infections in vaccinated or previously infected hamsters , 2022, bioRxiv.
[12] M. Schindler,et al. COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants , 2022, Scientific Reports.
[13] Naveen Dhawan,et al. Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review , 2022, Tropical medicine and infectious disease.
[14] D. Smoot,et al. Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic , 2022, Vaccines.
[15] N. Alharbi,et al. COVID-19 reinfection: A multicenter retrospective study in Saudi Arabia , 2022, Annals of thoracic medicine.
[16] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[17] Y. Kawaoka,et al. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters , 2022, Cell Reports.
[18] M. Kochańczyk,et al. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0–3.3 Days Can Be Explained by Immune Evasion , 2022, Viruses.
[19] C. Zheng,et al. Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines , 2022, Journal of medical virology.
[20] M. Diamond,et al. Advances and gaps in SARS-CoV-2 infection models , 2022, PLoS pathogens.
[21] A. Walls,et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement , 2021, bioRxiv.
[22] P. Maes,et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.
[23] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[24] R. Baric,et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine , 2021, Nature.
[25] Robert J. Fischer,et al. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 , 2021, Nature Communications.
[26] S. Elbashir,et al. mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates , 2021, Nature Immunology.
[27] T. Fiolet,et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.
[28] M. Beer,et al. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 , 2021, Nature Communications.
[29] H. Rammensee,et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity , 2021, Nature Communications.
[30] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[31] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[32] Barney S. Graham,et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.
[33] P. H. Cox,et al. The stability of 99mTc-DTPA and 99mTc-HIDA following ultrasonic nebulisation , 2004, European Journal of Nuclear Medicine.
[34] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .